Checkpoint Therapeutics, Inc. (CKPT)
4.260
0.00 (0.00%)
Inactive · Last trade price on May 29, 2025
Accolade Revenue
Checkpoint Therapeutics had revenue of $41.00K in the twelve months ending March 31, 2025, down -39.71% year-over-year. In the year 2024, Checkpoint Therapeutics had annual revenue of $41.00K, down -60.19%.
Revenue (ttm)
$41.00K
Revenue Growth
-39.71%
P/S Ratio
8,703.26
Revenue / Employee
$1,708
Employees
24
Market Cap
356.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.00K | -62.00K | -60.19% |
| Dec 31, 2023 | 103.00K | -89.00K | -46.35% |
| Dec 31, 2022 | 192.00K | -76.00K | -28.36% |
| Dec 31, 2021 | 268.00K | -801.00K | -74.93% |
| Dec 31, 2020 | 1.07M | -639.00K | -37.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCKPT News
- 2 months ago - Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewsWire
- 3 months ago - CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT - Business Wire
- 4 months ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 months ago - Sun Pharma to Acquire Checkpoint Therapeutics - PRNewsWire
- 8 months ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 8 months ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 9 months ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 9 months ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire